This RSS feed URL is deprecated
Zacks: Rubius Therapeutics Inc (RUBY) Given $33.75 Average Target Price by Analysts - Baseball Daily News
Rubius Therapeutics Inc (NASDAQ:RUBY) has received an average broker rating score of 1.13 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy ...altro »
Rubius Therapeutics, Inc. (RUBY) stock locked down along -4.39% to its 50- SMA - Nasdaq Place (press release)
Rubius Therapeutics, Inc. (RUBY) stock price moved Upswing along with the volume 0.11 million shares in Tuesday session. Shares are clocking price at $21.90 with change of 1.34%. Current trade price levels places RUBY's stock about -33.66% away from ...
Rubius Therapeutics, Inc. (RUBY) stock price is -4.39% lower to 200- SMA - Nasdaq Place (press release)
Current trade price levels places RUBY's stock about -33.66% away from the 52-week high and closed 11.34% away from the 52-week low. The total dollar value of all 71.78 million outstanding shares is 1.57 billion. The company's 3-months average volume ...
Rubius Therapeutics (RUBY): Keep Your Eyes on Healthcare Stock: - Stock Digest (press release)
Rubius Therapeutics (RUBY):. Every trading day indicate diverse behavior and trends about Rubius Therapeutics (RUBY) stock. Now we observed the different factors that seen on close of Wednesday session. At the end of the day, it's only a stock's ...
Shareholders Should Check If Insiders Own Shares In Rubius Therapeutics Inc (NASDAQ:RUBY) - Simply Wall St
Institutional investors transact in large blocks which can influence the momentum of stock prices, at least in the short-term, especially when there is a low level of public shares available on the market to trade. With an institutional ownership of 5 ...
Zacks: Analysts Expect Rubius Therapeutics Inc (RUBY) to Post -$0.36 Earnings Per Share - Fairfield Current
Equities research analysts predict that Rubius Therapeutics Inc (NASDAQ:RUBY) will announce ($0.36) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have ... Read More: Average Daily Trade Volume Explained · Get a free ...altro »
Stock-research Ratings: CSG Systems International, Inc. (CSGS), Rubius Therapeutics, Inc. (RUBY) - Analyst Journal
CSG Systems International, Inc. (NASDAQ:CSGS) tinted gains of +1.35% (+0.55 points) to US$41.31. The volume of 0.17 Million shares climbed down over an trading activity of 169.51 Million shares. EPS ratio determined by looking at last 12 month figures ...altro »
Rubius Therapeutics sees greater net loss in 2Q as its ramps up its cell therapy investments - Proactive Investors USA & Canada
Rubius Therapeutics Inc (NASDAQ:RUBY) announced its second-quarter results following its initial public offering in July. The biotech reported a ... of US$95mln through 2020. Shares of Rubius Therapeutics were flat at US$25.01 in Friday pre-market trading.altro »
Rubius Therapeutics (RUBY) Given Daily News Impact Score of 0.11 - Baseball Daily Digest
Rubius Therapeutics earned a news sentiment score of 0.11 on Accern's scale. Accern also assigned news coverage about the company an impact score of 45.5402218910935 out of 100, indicating that recent press coverage is somewhat unlikely to have an ...
Biotech IPOs Are Booming … but for How Long? - BioSpace (press release) (blog)
Companies that sold stock for the first time in 2018 include Translate Bio Inc., which is using messenger RNA to develop drugs for rare diseases such as cystic fibrosis, and Neon Therapeutics Inc., which describes itself as a platform for developing ...